4D Molecular Therapeutics, Inc. Common Stock

Day range

$10.62 – $11.29

Open

$10.74

Prev close

$10.80

Volume

524.67K

Market cap

$596.64M

Shares out

55.24M

P/E

—

P/S

6.48

P/B

1.46

P/FCF

—

ROE

-44.0%

ROA

-36.4%

Debt/Equity

0.05

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 28, 2026

  On September 28, 2026, 4D Molecular Therapeutics, Inc. reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema ("DME"). The Company also reported 2-year data from the SPECTRA clinical trial.

• Quarterly earningsAug 13, 2026

  On August 13, 2026, 4D Molecular Therapeutics, Inc. ("4DMT") announced its financial results for the three months ended June 30, 2026. A copy of 4DMT's press release, titled "4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

• Clinical trial resultsJul 20, 2026

  On July 18, 2026, 4D Molecular Therapeutics, Inc. (the "Company") reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration ("wet AMD") population. Phase 2b Efficacy Results Through 2 Years: Consistent maintenance of best corrected visual acuity ("BCVA"), Consistent control of central subfield thickness ("CST") as measured by optical coherence tomography, Consistent, durable and clinically meaningful reduction in treatment burden.

• Credit facility drawJun 29, 2026

  A Tranche 1A Loan of $20.0 million was drawn on the Closing Date. The Tranche 1A Loan bears interest at a floating rate based upon an annual interest rate of the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.00% and (ii) 8.75%, payable monthly in arrears.

• Quarterly earningsMay 7, 2026

  On May 7, 2026, 4D Molecular Therapeutics, Inc. ("4DMT") announced its financial results for the three months ended March 31, 2026. A copy of 4DMT's press release, titled "4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Days to cover

9.3

Short interest

11.24M

Avg volume

1.2M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• 4DMT to Participate in Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Aug 25, 2026
• 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
  positiveGlobeNewswire Inc.· Jul 18, 2026
• 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
  positiveGlobeNewswire Inc.· Jun 29, 2026
• Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
  positiveGlobeNewswire Inc.· Jun 18, 2026
• 4DMT to Participate in Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Feb 19, 2026